These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Survival of tuberculous bacilli in combined treatments including rifampicin]. Kreis B; Pretet S Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940 [No Abstract] [Full Text] [Related]
24. [Comparative study of the development of rifomycin blood levels in humans by 2 different microbiologic methods]. Canetti G; Djurovic V; Le Lirzin M; Thibier R; Lepeuple A Rev Tuberc Pneumol (Paris); 1970; 34(1):93-106. PubMed ID: 4996249 [No Abstract] [Full Text] [Related]
25. Susceptibilities of Mycobacterium tuberculosis to isoniazid and rifampin on blood agar. Coban AY; Bilgin K; Uzun M; Tasdelen Fisgin N; Akgunes A; Cihan CC; Birinci A; Durupinar B J Clin Microbiol; 2005 Apr; 43(4):1930-1. PubMed ID: 15815022 [TBL] [Abstract][Full Text] [Related]
26. [Number of rifampicin- and ethambutol-resistant variants in strains of atypical mycobacteria pathogenic for man, on Loewenstein-Jensen media]. Le Lirzin M; Boisvert H Ann Inst Pasteur (Paris); 1971 Apr; 120(4):549-59. PubMed ID: 5564197 [No Abstract] [Full Text] [Related]
27. [The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays]. Skotnikova OI; Galkina KIu; Nosova EIu; Krasnova MA; Moroz AM Probl Tuberk Bolezn Legk; 2005; (8):42-5. PubMed ID: 16209020 [TBL] [Abstract][Full Text] [Related]
28. Susceptibility testing of Mycobacterium tuberculosis: comparison of the BACTEC TB-460 method and flow cytometric assay with the proportion method. DeCoster DJ; Vena RM; Callister SM; Schell RF Clin Microbiol Infect; 2005 May; 11(5):372-8. PubMed ID: 15819863 [TBL] [Abstract][Full Text] [Related]
29. [Metabolic behavior of Mycobacterium tuberculosis strain H37 Ra under action of rifampicin, comparison with isoniazid]. Le Cam M; Madec Y; Bernard S Ann Inst Pasteur (Paris); 1971 Feb; 120(2):186-95. PubMed ID: 4396428 [No Abstract] [Full Text] [Related]
30. [Study of the biological characteristics of strains of M. tuberculosis resistant to isoniazid and rifampin]. Diaconescu C; Iacob L Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1984; 33(2):151-62. PubMed ID: 6093222 [No Abstract] [Full Text] [Related]
31. [Antimicrobial susceptibility testing for Mycobacterium tuberculosis by measuring mycobacterial adenosine triphosphate]. Yamazaki T; Sato N; Yamashita K; Okazawa Y; Miyao H; Tanno K Rinsho Byori; 1999 Feb; 47(2):170-5. PubMed ID: 10097635 [TBL] [Abstract][Full Text] [Related]
32. [Molecular mechanisms of mycobacterium tuberculosis strains resistance to rifampicin and isoniazid]. Stepanshina VN; Panfertsev EA; Mitrofanova GN; Korobova OV; Stepanshin IuG; Shemiakin IG; Medvedeva IM Probl Tuberk; 2000; (1):32-6. PubMed ID: 10750428 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of rifampicin action on mycobacterial cells. Consideration to the potentiation problem of antimycobacterial treatment. Trnka L Acta Tuberc Pneumol Belg; 1969; 60(3):356-65. PubMed ID: 4984419 [No Abstract] [Full Text] [Related]
34. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001 [TBL] [Abstract][Full Text] [Related]
35. Drug-resistance in M. tuberculosis and other mycobacteria. David HL Clin Chest Med; 1980 May; 1(2):227-30. PubMed ID: 6794975 [No Abstract] [Full Text] [Related]
36. [On the bactericidal activity in vivo of Rifampicin alone or associated with isoniazid]. Nitti V; Ninni A; Natali P Arch Tisiol Mal Appar Respir; 1967 Oct; 22(10):859-70. PubMed ID: 4975183 [No Abstract] [Full Text] [Related]
37. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. Ahmad Z; Sharma S; Khuller GK FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463 [TBL] [Abstract][Full Text] [Related]
39. On the possibility of cross-resistance between rifampicin and clofazimine in mycobacteria--a laboratory study. Urbanczik R Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Aug; 260(1):113-6. PubMed ID: 3933210 [TBL] [Abstract][Full Text] [Related]
40. [Comparison of in vitro antimycobacterial activities of ansamycin and rifampicin]. Tsukamura M; Mizuno S; Toyama H; Ichiyama S Kekkaku; 1986 Oct; 61(10):497-503. PubMed ID: 3100853 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]